These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38520434)

  • 1. Mortality Benefit Among Primary Prevention Implantable Cardioverter-Defibrillator Recipients on Contemporary Heart Failure Treatment.
    Ahmed A; Auricchio A; Mittal S; Pickett RA; Wilkoff BL; Jacobsen LD; Marti AK; Holbrook RW; Soderlund DM; Curtis AB
    JACC Clin Electrophysiol; 2024 May; 10(5):916-926. PubMed ID: 38520434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
    Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
    J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
    Schrage B; Uijl A; Benson L; Westermann D; Ståhlberg M; Stolfo D; Dahlström U; Linde C; Braunschweig F; Savarese G
    Circulation; 2019 Nov; 140(19):1530-1539. PubMed ID: 31476893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.
    Bhavnani SP; Pavuluri V; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Pacing Clin Electrophysiol; 2013 Jul; 36(7):878-84. PubMed ID: 23614760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
    Pun PH; Hellkamp AS; Sanders GD; Middleton JP; Hammill SC; Al-Khalidi HR; Curtis LH; Fonarow GC; Al-Khatib SM
    Nephrol Dial Transplant; 2015 May; 30(5):829-35. PubMed ID: 25404241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death.
    Bilchick KC; Stukenborg GJ; Kamath S; Cheng A
    J Am Coll Cardiol; 2012 Oct; 60(17):1647-55. PubMed ID: 23021331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of baseline heart failure burden on post-implantable cardioverter-defibrillator mortality among medicare beneficiaries.
    Chen CY; Stevenson LW; Stewart GC; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
    J Am Coll Cardiol; 2013 May; 61(21):2142-50. PubMed ID: 23541973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
    Zhang Y; Kennedy R; Blasco-Colmenares E; Butcher B; Norgard S; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Guallar E; Tomaselli GF; Cheng A
    Heart Rhythm; 2014 Aug; 11(8):1377-83. PubMed ID: 24793459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?
    Levy WC; Li Y; Reed SD; Zile MR; Shadman R; Dardas T; Whellan DJ; Schulman KA; Ellis SJ; Neilson M; O'Connor CM;
    JACC Clin Electrophysiol; 2017 Mar; 3(3):291-298. PubMed ID: 28553663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.
    Chen CY; Stevenson LW; Stewart GC; Bhatt DL; Desai M; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
    BMJ; 2015 Jul; 351():h3529. PubMed ID: 26174233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.
    Kristensen SL; Levy WC; Shadman R; Nielsen JC; Haarbo J; Videbæk L; Bruun NE; Eiskjær H; Wiggers H; Brandes A; Thøgersen AM; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Signorovitch J; Køber L; Thune JJ
    JACC Heart Fail; 2019 Aug; 7(8):717-724. PubMed ID: 31302052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.
    Al-Khatib SM; Hellkamp A; Bardy GH; Hammill S; Hall WJ; Mark DB; Anstrom KJ; Curtis J; Al-Khalidi H; Curtis LH; Heidenreich P; Peterson ED; Sanders G; Clapp-Channing N; Lee KL; Moss AJ
    JAMA; 2013 Jan; 309(1):55-62. PubMed ID: 23280225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
    Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Sharma A; Al-Khatib SM; Ezekowitz JA; Cooper LB; Fordyce CB; Michael Felker G; Bardy GH; Poole JE; Thomas Bigger J; Buxton AE; Moss AJ; Friedman DJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Peterson ED; Inoue LYT; Sanders GD
    Eur J Heart Fail; 2018 Jun; 20(6):1031-1038. PubMed ID: 29761861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioverter-defibrillator reduces mortality risk in eligible ischemic and non-ischemic cardiomyopathy patients: Sub-analysis of the multi-center Improve SCA study.
    Singh B; Hsieh YC; Liu YB; Lin KH; Joung B; Rodriguez DA; Chasnoits AR; Huang D; Zhang S; O'Brien JE; Lexcen DR; Cerkvenik J; Van Dorn B; Ching CK
    Indian Heart J; 2023; 75(2):115-121. PubMed ID: 36736459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.